Transformative Drug Innovations Reshaping Myeloma Treatment
A special issue of Cancers (ISSN 2072-6694). This special issue belongs to the section "Cancer Therapy".
Deadline for manuscript submissions: 31 January 2026 | Viewed by 43
Special Issue Editor
Interests: plasma cell dyscrasias; monoclonal paraprotein; amyloidosis
Special Issue Information
Dear Colleagues,
We are delighted to announce a Special Issue in the Journal Cancers, entitled “Transformative Drug Innovations Reshaping Myeloma Treatment”. This Issue aims to showcase and explore groundbreaking drug therapies revolutionizing the clinical landscape of multiple myeloma management. We welcome submissions that address recent advancements in targeted treatments, cellular therapies, immunotherapies, and novel combination regimens that have demonstrated potential in overcoming resistance mechanisms and improving patient outcomes. Potential topics include the molecular mechanisms driving drug responses, clinical trial updates, translational research insights, and future directions in personalized medicine. Submissions may consist of original research articles, comprehensive reviews, case reports, or cutting-edge perspectives. Our goal is to provide a platform that fosters interdisciplinary dialogue and facilitates the translation of innovative research into clinical practice. We invite you to share your expertise and insights, thereby contributing to the evolving narrative of myeloma treatment.
Dr. Despina Fotiou
Guest Editor
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cancers is an international peer-reviewed open access semimonthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- multiple myeloma
- cellular therapy
- immunotherapy
Benefits of Publishing in a Special Issue
- Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
- Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
- Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
- External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
- Reprint: MDPI Books provides the opportunity to republish successful Special Issues in book format, both online and in print.
Further information on MDPI's Special Issue policies can be found here.
